Hypomethylation associated enhanced transcription of trefoil factor-3 mediates tamoxifen-stimulated oncogenicity of ER+ endometrial carcinoma cells

Tamoxifen (TAM) is widely used as an adjuvant therapy for women with breast cancer (BC). However, TAM possesses partial oestrogenic activity in the uterus and its use has been associated with an increased incidence of endometrial carcinoma (EC). The molecular mechanism for these observations is not...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Pandey, Vijay, Zhang, Min, Chong, Qing-Yun, You, Mingliang, Raquib, Ainiah Rushdiana, Pandey, Amit K., Liu, Dong-Xu, Liu, Liang, Ma, Lan, Jha, Sudhakar, Wu, Zheng-Sheng, Zhu, Tao, Lobie, Peter E.
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2017
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5652779/
https://ncbi.nlm.nih.gov/pubmed/29100386
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.20461
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados